Sandra Swain

33PUBLICATIONS
124CO-AUTHORS
Gene and molecular therapyMolecular targetsPharmacogenomicsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Feb 08, 2025
A Randomized Hybrid-Effectiveness Trial Comparing Pharmacogenomics (PGx) to Standard Care: The PGx Applied to Chronic Pain Treatment in Primary Care (PGx-ACT) Trial.

D Max Smith, Rut Beyene, Paul Kolm

|Jan 31, 2025
Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers.

Arielle L Heeke, Andrew Elliott, Kaitlyn O'Keefe

|Jan 31, 2025
A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice.

Teresa T Ho, D Max Smith, Christina L Aquilante

|Sep 30, 2024
Pharmacokinetics and pharmacogenomics of ribociclib in black patients with metastatic breast cancer the LEANORA study.

Ilana Schlam, D Max Smith, Cody Peer

|Aug 26, 2024
Pharmacokinetics and Pharmacogenomics of Ribociclib in Black Patients with Metastatic Breast Cancer: The LEANORA study.

Sandra Swain, Ilana Schlam, D Max Smith

|Jul 24, 2024
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial.

Priya Rastogi, Hanna Bandos, Peter C Lucas

Pageof 6

Frequent Collaborators

6 joint publications

D Max Smith

5 joint publications

Claudine Isaacs

4 joint publications

Christopher Gallagher

3 joint publications

Charles E Geyer